BOIRON : Activity in the third quarter of 2015

le
0

(Unaudited data)


Development of business in the third quarter (variation at current rate)

thousands of euros 1st Quarter 2nd Quarter 3rd Quarter
2014 2015 Var. 15/14 2014 2015 Var. 15/14 2014 2015 Var. 15/14
France 82,749 89,584 + 8.3% 74,269 76,864 + 3.5% 92,466 97,767 + 5.7%
Europe (excluding France) 39,967 40,657 + 1.7% 33,570 29,943 - 10.8% 62,758 50,614 - 19.4%
North America 12,662 17,193 + 35.8% 10,625 12,894 + 21.4% 13,109 16,055 + 22.5%
Other countries 4,831 4,622 - 4.3% 2,943 3,816 + 29.7% 3,779 3,594 - 4.9%
Group total 140,209 152,056 + 8.4% 121,407 123,517 + 1.7% 172,112 168,030 - 2.4%

 

thousands of euros 1st Quarter 2nd Quarter 3rd Quarter
2014 2015 Var. 15/14 2014 2015 Var. 15/14 2014 2015 Var. 15/14
Non-proprietary Homeopathic Medicines 77,919 79,191 + 1.6% 73,072 74,354 + 1.8% 72,957 73,677 + 1.0%
OTC Specialties 62,196 72,880 +17.2% 48,058 49,030 + 2.0% 99,025 94,328 - 4.7%
Other 94 -15 - 277 133 - 52.0% 130 25 - 80.8%
Group total 140,209 152,056 + 8.4% 121,407 123,517 + 1.7% 172,112 168,030 - 2.4%


Cumulative activity as of the end of september 2015

thousands of euros 2014 2015 Variation at current exchange rates Variation at constant exchange rates
France 249,484 264,215 + 5.9% + 5.9%
Europe (excluding France) 136,295 121,214 - 11.1% - 7.1%
North America 36,396 46,142 + 26.8% + 7.1%
Other countries 11,553 12,032 + 4.1% + 6.7%
Group total 433,728 443,603 + 2.3% + 1.9%

 

thousands of euros 2014 2015 Variation at current exchange rates Variation at constant exchange rates
Non-proprietary Homeopathic Medicines 223,948 227,222 + 1.5% + 0.5%
OTC Specialties 209,279 216,238 + 3.3% + 3.6%
Other 501 143 - 71.5% - 48.9%
Group total 433,728 443,603 + 2.3% + 1.9%


Highlights of the third quarter

  • Sales revenue in the 3rd quarter of 2015 are decreasing by 2.4% in comparison to 2014 (-1% at constant rate) with a revenue growth in France and the USA, but in decline mainly in Russia and to a lesser extent in Italy and Poland.
  • Boiron announced its plan to locate its future logistic platform in the town of Les Olmes, near Tarare in the West of Lyon. Meanwhile, construction work for the site extension of Messimy have begun.
  • Boiron put on the French market a new cough syrup, Stodaline®.


Outlook

  • Boiron continues its involvement in the development of homeopathy in the world.
  • Given the development of the activity at the end of September 2015 and the unpredictability of seasonal pathology of the last quarter, the operational income may not reach the same level as in 2014.


Our next update: January 21, 2016 at market close, publication of the sales revenue for the year 2015.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com


Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-41752-BOI-161015-CA-T3-15-GB.pdf

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.


Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant